Breast Cancer Research and Treatment

, Volume 36, Issue 1, pp 71–81 | Cite as

Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases

  • Gaëtan MacGrogan
  • Françoise Bonichon
  • Isabelle de Mascarel
  • Monique Trojani
  • Michel Durand
  • Antoine Avril
  • Jean-Michel Coindre
Report

Summary

P53 immunohistochemical detection using DO7 antibody on 942 cases of previously untreated breast invasive ductal carcinoma (IDC) with a median follow up of 117.9 months (89 to 160) was performed.

Three hundred and three (32%) tumors were positive. All positive tumors were taken into account, positivity ranging from 1 to 100% of tumoral cells. The Chi square test showed significant negative correlation between p53 positivity and age (p = 0.01), estrogen receptor status (p < 0.0001), and progesterone receptor status (p = 0.0005), and significant positive correlation with tumor grade according to the Scarff, Bloom and Richardson system (SBR Grade) (p < 0.0001). There was no significant association with tumor size or nodal status.

Concerning the univariate analysis, in the whole group and node-positive group (n = 544) p53 positivity was highly significant for overall survival (OS) (p < 0.0001 and p = 0.0003), disease-free interval (DFI) (p = 0.0001 and p = 0.0005), and metastasis-free interval (MFI) (p < 0.0001 and p = 0.0003). In the node-negative group (n = 398), p53 was significant with respect to OS (p = 0.01) and DFI (p = 0.04). P53 positivity came out as an independent prognostic parameter in the multivariate analysis in the whole group and the node-positive group, though of minor significance compared to axillary lymph node status, SBR grade, progesterone receptor status, and tumor size.

Key words

P53 invasive ductal carcinoma immunohistochemistry prognosis tumor suppressor genes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262–7266, 1992Google Scholar
  2. 2.
    Coles C, Condie A, Chetty U, Steel CM, Evans J, Prosser J: P53 mutations in breast cancer. Cancer Res 52: 5291–5298, 1992Google Scholar
  3. 3.
    Milner J, Medcalf EA: Cotranslation of activated mutant p53 with wildtype drives the wild-type p53 protein into the mutant conformation. Cell 65: 765–774, 1991Google Scholar
  4. 4.
    Allred CD, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206, 1993Google Scholar
  5. 5.
    Martinazzi M, Crivelli F, Zampatti C, Martinazzi S: Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 100: 213–217, 1993Google Scholar
  6. 6.
    Soubeyran I, Coindre JM, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A: Immunohistochemical determination of PS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat (in press)Google Scholar
  7. 7.
    Barbareshi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P: P53 and c-erbB-2 protein expression in breast carcinomas, an immunohistochemical study including correlation with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98: 408–418, 1992Google Scholar
  8. 8.
    Bhargava V, Thor A, Deng G, Ljung CM, Moore DH II, Waldman F, Benz C, Goodson W III, Mayall B, Chew K, Smith HS: The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 7: 361–368, 1994Google Scholar
  9. 9.
    Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G: Abnormal p53 immunoactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat 421: 291–295, 1992Google Scholar
  10. 10.
    Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F: Vimentin and p53 expression on epidermal growth factor receptor-positive and estrogen receptor-negative breast carcinomas. Br J Cancer 57: 353–357, 1988Google Scholar
  11. 11.
    Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: P53 expression in breast cancer. Int J Cancer 41: 178–183, 1988Google Scholar
  12. 12.
    Davidoff AM, Kerns BJM, Pence JC, Marks JR, Iglehart JD: P53 alterations in all stages of breast cancer. J Surg Oncol 48: 260–267, 1991Google Scholar
  13. 13.
    Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M: Nuclear p53 protein accumulates preferentially in medullary and high grade ductal but rarely in lobular breast carcinomas. Am J Pathol 142: 669–674, 1993Google Scholar
  14. 14.
    Friedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641–3647, 1993Google Scholar
  15. 15.
    Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109–1114, 1992Google Scholar
  16. 16.
    Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJ, Angus B, Horne CHW: P53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75–81, 1991Google Scholar
  17. 17.
    Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO: P53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression and oestrogen receptor. Br J Cancer 66: 683–588, 1992Google Scholar
  18. 18.
    Thor AD, Moore DH, Edgerton S, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845–855, 1992Google Scholar
  19. 19.
    Visscher DW, Sarkar FH, Wykes S, Kothari K, Macoska J, Crissman J: Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med 117: 973–976, 1993Google Scholar
  20. 20.
    Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469–476, 1993Google Scholar
  21. 21.
    Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: P53 as an independent prognostic marker in lymph node negative breast cancer patients. J Natl Cancer Inst 85: 965–970, 1993Google Scholar
  22. 22.
    Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL: Prognostic significance of Tp53 alterations in breast carcinoma. Br J Cancer 68: 540–548, 1993Google Scholar
  23. 23.
    Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF: P53 gene mutations and steroid receptor status in breast cancer. Cancer 73: 2147–2156, 1994Google Scholar
  24. 24.
    Mazars P, Spinardi L, Bencheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C: P53 mutations occur in aggressive breast cancer. Cancer Res 52: 3918–3923, 1992Google Scholar
  25. 25.
    Merlo GR, Bernardi A, Diella F, Venesio T, Cappa APM, Callahan R, Liscia DS: In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int J Cancer 54: 531–535, 1993Google Scholar
  26. 26.
    Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau MM, Callahan R, Minna JD: Mutation in the p53 gene in primary human breast cancers. Cancer Res 51: 6194–6198, 1991Google Scholar
  27. 27.
    Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM: P53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathologic parameters. Int J Cancer 50: 528–532, 1992Google Scholar
  28. 28.
    Thoralcius S, Borresen AL, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53: 1637–1641, 1993Google Scholar
  29. 29.
    Kerns BJM, Jordan PA, Moore MBH, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR: P53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 40: 1047–1051, 1992Google Scholar
  30. 30.
    Baas IO, Mulder JW, Offerhaus JA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5–12, 1994Google Scholar
  31. 31.
    Lambkin HA, Carmel MM, Kelehan P: Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 172: 13–18, 1994Google Scholar
  32. 32.
    Terada T, Shimizu K, Izumi R, Nakanuma Y: P53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 7: 249–252, 1994Google Scholar
  33. 33.
    Linden MD, Nathanson SD, Zarbo RJ: Evaluation of anti-p53 antibody staining. Quality control and technical considerations. Appl Immunohistochem 2: 218–224, 1994Google Scholar
  34. 34.
    Lipponen P, Ji H, Aaltomaa JS, Syrjanen S, Syrjanen K: P53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51–56, 1993Google Scholar
  35. 35.
    Hall PA, Lane DP: P53 in tumour pathology: can we trust immunohistochemistry? Revisited. J Pathol 172: 1–4, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Gaëtan MacGrogan
    • 1
  • Françoise Bonichon
    • 1
  • Isabelle de Mascarel
    • 1
  • Monique Trojani
    • 1
  • Michel Durand
    • 1
  • Antoine Avril
    • 1
  • Jean-Michel Coindre
    • 1
    • 2
  1. 1.Institut BergoniéBordeauxFrance
  2. 2.Université de Bordeaux IIBordeauxFrance

Personalised recommendations